Clinical Trials

Belfast – October 14, 2026 -- Cumulus Neuroscience and Transpharmation Ltd. have formed a strategic partnership to align EEG and behavioral endpoints from preclinical models through first-in-human trials, targeting a therapeutic area where an estimated 6.7% of candidates progress from nonclinical development to FDA approval (Sertkaya et al., JAMA Netw Open, 2024).

Partners target the measurement break between animal studies and Phase 1

The two companies will jointly advise biopharma sponsors preparing for first-in-human studies. They will recommend which EEG paradigms to run preclinically based on how the same measures will be captured in the clinic. Each company will no longer scope its portion of a programme in isolation.

Research Triangle Park – October 13, 2026 -- IQVIA has selected four Veeva applications (CTMS, eTMF, Study Startup and Site Connect) as enterprise standards for its clinical development studies, extending a partnership that previously covered Veeva's EDC.

IQVIA and Veeva widen the clinical technology tie-up beyond EDC

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced the expansion on Oct. 13, 2026. The companies say the combined offering is intended to raise trial speed and efficiency, strengthen site centricity and improve decision-making.

All Veeva clinical solutions are also available through IQVIA for sponsors that want a full Veeva technology stack.

Seoul – October 13, 2026 -- South Korea's GCCL and LabConnect signed a memorandum of understanding on October 12 to link their North American and Asia-Pacific (APAC) central laboratory capabilities for joint sales and project execution in global clinical trials.

Partners formalize a relationship spanning more than 20 years

The agreement builds on a collaboration that has run for more than 20 years. It aims to improve the operational efficiency of global trial projects by combining each company's regional expertise. Financial terms were not disclosed.

The signing took place at GCCL's headquarters. GCCL CEO Kwan-goo Cho attended, as did LabConnect's Jeff Mayhew, Founder and Strategic Commercial Advisor, and Joshua Gentile, Senior Vice President, Head of Commercial Sales and Marketing.

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to run the first part of its two-part XRX-OXY-102 gout study in Canada, a move it expects to speed delivery of the clinical data needed for a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

XORTX prepares Health Canada filing in parallel with FDA track

The company has outlined an anticipated Clinical Trial Application (CTA) to Health Canada for its XRx-026 gout program. The study evaluates XORLO, XORTX's proprietary formulation of oxypurinol, a xanthine oxidase inhibitor. Drug development teams have been preparing the CTA in parallel with the planned FDA NDA submission.

Jersey City – October 12, 2026 -- Subcutaneous (SC) infliximab delivered clinical remission in 71.4% of matched patients with ileum-dominant Crohn's disease at Week 54, against 51.4% for intravenous (IV) infliximab, according to a late-breaking analysis Celltrion USA will present for ZYMFENTRA (infliximab-dyyb) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.

Matched analysis shows wider endoscopic gap for SC infliximab at Week 54

The pooled analysis used individual patient data from four infliximab registrational studies. Of 884 patients, 200 with ileal or ileocolonic Crohn's disease met eligibility criteria. They received either SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. A 1:1 propensity score-matched analysis included 70 patients per arm.

SC infliximab outperformed IV infliximab on all three measures in the matched population:

Tokyo – October 07, 2026 -- Astellas Pharma Inc. (TSE: 4503) will present 21 abstracts from its oncology portfolio at the European Society for Medical Oncology Congress 2026, running October 23-27 in Madrid, Spain.

Enfortumab vedotin combination shows longest follow-up data yet in urothelial cancer

Presentations on PADCEV (enfortumab vedotin) plus pembrolizumab include the longest follow-up reported to date for patients with locally advanced or metastatic urothelial cancer, alongside subgroup and treatment-setting analyses. Additional data cover trials in progress evaluating bladder preservation strategies in muscle-invasive bladder cancer.

Detroit – – October 06, 2026 -- The Barbara Ann Karmanos Cancer Institute has appointed Stefan C. Grant, M.D., to a newly created role as associate center director and medical director of the Karmanos Cancer Network, giving the oncologist oversight of clinical trial access across 13 McLaren Health Care sites outside metro Detroit. Dr. Grant began the position in September, adding the titles of vice chair of clinical operations and co-leader of the Thoracic Oncology Multidisciplinary Team.

New role targets trial access gap across 13 Michigan sites

The associate center director position did not previously exist at Karmanos. Dr. Grant will work with oncology teams at McLaren's network locations to expand clinical trial availability for patients who currently must travel to Detroit, according to Boris Pasche, M.D., Ph.D., president and CEO of Karmanos.

Holon, Israel – October 06, 2026 -- Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN) will join a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, a virtual event running October 8-9, 2026.

Management confirms October 8 session with live investor webcast

The fireside chat is scheduled for Thursday, October 06, 2026, at 9:30 AM ET. A live webcast will stream via the Investor Relations events page on Compugen's website, with a replay available afterward.

Dallas – October 06, 2026 -- Nanoscope Therapeutics will present four-year durability data from its RESTORE Phase 2b/3 trial of optogenetic therapy MCO-010 in retinitis pigmentosa at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, running October 8–13 in New Orleans.

Four-year REMAIN data to show durability of vision gains in retinitis pigmentosa

Dr. Kenneth C. Fan will present the REMAIN study results on Sunday, October 11, highlighting sustained vision improvement among patients treated with MCO-010 in the RESTORE trial. A separate scientific poster from Dr. David S. Boyer will detail vision improvement with sonpiretigene isteparvovec in dry age-related macular degeneration, drawn from what the company describes as the first direct-to-Phase 2 randomized controlled trial in that indication.

Shanghai/Hong Kong – – October 03, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) will present preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2026), running November 4-8 at the Phoenix Convention Center in Arizona.

Chief Scientific Officer to present CD2-based platform data on November 6

Dr. Bing Hou, Antengene's Chief Scientific Officer, will deliver the presentation titled "A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking," filed under Abstract 15749. The session, categorized as Rapid Oral - Basic 1, is scheduled for 12:30 PM to 1:30 PM Eastern Time on November 6, corresponding to 1:30 AM to 2:30 AM Beijing time on November 7.